Terms ending in 2033
Every in-force patent on AstraZeneca AB's record whose computed term ends in 2033, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,309,245 | Beta-Lactamase Inhibitor Compounds In force · High confidence | Entasis Therapeutics Limited | In force | High confidence | |
| US 9,623,014 | Beta-Lactamase Inhibitor Compounds In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 9,487,525 | Crystalline Forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide In force · High confidence | AstraZeneca AB | In force | High confidence | |
| US 10,039,766 | Crystalline Forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 10,548,882 | Camsylate Salt In force · Medium confidence | AstraZeneca AB | In force | Medium confidence | |
| US 9,834,598 | Antibodies to Amyloid Beta In force · High confidence | MedImmune Limited | In force | High confidence | |
| US 10,662,239 | Antibodies to Amyloid Beta In force · Low confidence | MedImmune Limited | In force | Low confidence | |
| US 11,286,297 | Antibodies to Amyloid Beta In force · Low confidence | MedImmune Limited | In force | Low confidence | |
| US 12,344,664 | Antibodies to Amyloid Beta In force · Medium confidence | MedImmune Limited | In force | Medium confidence | |
| US 10,994,082 | Inhaler Counter In force · High confidence | AstraZeneca AB | In force | High confidence | |
| 2 more term ends in 2033 · Pro | |||||
10 of 12 patents shown. Soonest term end first, then patent number.
Pro members see all 12.
6 of these are in force and held by AstraZeneca AB.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.